Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 000513.SZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 000513.SZ and 80,000+ other tickers.
See exactly how 000513.SZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 000513.SZ and 80,000+ other tickers.
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal…
No recent news available.